These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 27343420)

  • 1. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia.
    Boban M; Zulj M; Persic V; Medved I; Zekanovic D; Vcev A
    Int J Cardiol; 2016 Sep; 219():277-81. PubMed ID: 27343420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cardiovascular treatments and systolic dysfunction on nutritional risk in patients with ischemic and valvular heart disease.
    Boban M; Persic V; Petricevic M; Manola S; Boban L; Vcev A
    J Am Coll Nutr; 2015; 34(2):159-66. PubMed ID: 25751132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Connections between nutritional status and proton pump inhibitor therapy in patients scheduled for cardiovascular rehabilitation after treatment for ischaemic and valvular heart disease.
    Boban M; Persic V; Petricevic M; Biocina B; Sipic T; Pehar-Pejcnovic V; Balen S; Zulj M; Vcev A
    Kardiol Pol; 2016; 74(5):461-468. PubMed ID: 26412474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of proton pump inhibitors and risk of ischemic events in the general population.
    Casula M; Scotti L; Galimberti F; Mozzanica F; Tragni E; Corrao G; Catapano AL
    Atherosclerosis; 2018 Oct; 277():123-129. PubMed ID: 30212680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term proton pump inhibitor therapy on hemoglobin and serum iron levels after sleeve gastrectomy.
    Sharma N; Chau WY; Dobruskin L
    Surg Obes Relat Dis; 2019 Oct; 15(10):1682-1689. PubMed ID: 31422079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
    Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G
    Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.
    Wang YF; Chen YT; Luo JC; Chen TJ; Wu JC; Wang SJ
    Am J Gastroenterol; 2017 Jul; 112(7):1084-1093. PubMed ID: 28397874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of proton pump inhibitors, dose-response relationship and associated risk of ischemic stroke and myocardial infarction.
    Sehested TSG; Gerds TA; Fosbøl EL; Hansen PW; Charlot MG; Carlson N; Hlatky MA; Torp-Pedersen C; Gislason GH
    J Intern Med; 2018 Mar; 283(3):268-281. PubMed ID: 29024109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Aliment Pharmacol Ther; 2012 Jan; 35(1):165-74. PubMed ID: 22050009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
    Ghebremariam YT; Cooke JP; Khan F; Thakker RN; Chang P; Shah NH; Nead KT; Leeper NJ
    Vasc Med; 2015 Aug; 20(4):309-16. PubMed ID: 25835348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis?
    Mikolasevic I; Milic S; Stimac D; Zaputovic L; Lukenda Zanko V; Gulin T; Jakopcic I; Klaric D; Gulin M; Orlic L
    Eur J Intern Med; 2016 May; 30():99-103. PubMed ID: 26905320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of oral proton pump inhibitors is not associated with harm in patients with chronic heart failure in an ambulatory setting.
    Oudit GY; Bakal JA; McAlister FA; Ezekowitz JA
    Eur J Heart Fail; 2011 Nov; 13(11):1211-5. PubMed ID: 21831912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
    Shih CJ; Chen YT; Ou SM; Li SY; Chen TJ; Wang SJ
    Int J Cardiol; 2014 Nov; 177(1):292-7. PubMed ID: 25499395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
    de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
    Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients.
    Shikata T; Sasaki N; Ueda M; Kimura T; Itohara K; Sugahara M; Fukui M; Manabe E; Masuyama T; Tsujino T
    Circ J; 2015; 79(1):193-200. PubMed ID: 25392070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.
    Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N
    Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.
    Meli M; Raffa MP; Malta R; Morreale I; Aprea L; D'Alessandro N
    Int J Clin Pharm; 2015 Dec; 37(6):1152-61. PubMed ID: 26319396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.